KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 6037 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Baseline Interleukin-10 Levels as a Predictive Biomarker for Achieving Clinical Response With Abatacept in Patients Who Were Disease-Modifying Antirheumatic Drug Naive and Anti-Citrullinated Protein Antibody Positive With Early Rheumatoid Arthritis. PMID 41733109 · Arthritis Rheumatol · 2026-Feb-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of Age on Patient-Reported Outcomes with First-Line Camrelizumab plus Rivoceranib versus Sorafenib in Adults with Unresectable Hepatocellular Carcinoma: Post Hoc Analyses of the CARES-310 Open-Label, Randomized, Phase 3 Trial. PMID 41972014 · Liver Cancer · 2026-Feb-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Survival Assessment by Central Review vs. Local Investigator in Metastatic Melanoma: A Systematic Review and Meta-Analysis. PMID 41749963 · Cancers (Basel) · 2026-Feb-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Live biotherapeutic product IBP-9414 (L. reuteri) in very low birth weight infants: the Connection Study. PMID 41721054 · Pediatr Res · 2026-Feb-20 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia. PMID 41363770 · J Clin Oncol · 2026-Feb-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Multi-modal integrated intervention combining exercise, anti-inflammatory, and dietary advice (MMIEAD) for adults with kidney cachexia: protocol for a mixed-methods feasibility cluster randomised controlled trial and process evaluation. PMID 41715172 · Pilot Feasibility Stud · 2026-Feb-19 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The RECLAIM adaptive platform trial for the evaluation of treatments for post-COVID condition in the Netherlands: core protocol. PMID 41715140 · Trials · 2026-Feb-19 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Intravenous Fosfomycin in Complicated Urinary Tract Infection. PMID 41711122 · Ann Pharmacother · 2026-Feb-19 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials. PMID 41175364 · Blood · 2026-Feb-19 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy of Pirtobrutinib Monotherapy in Treatment-Naïve Chronic Lymphocytic Leukemia: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. PMID 41749915 · Cancers (Basel) · 2026-Feb-18 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration). PMID 41714204 · Eur Urol Focus · 2026-Feb-18 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 5 Figure · 9 Panel · risk visible
Evidence-Based Self-Management Strategies for Fibromyalgia: Foundations for Digital Therapeutic Applications. PMID 41701966 · Interact J Med Res · 2026-Feb-17 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Understanding the Unique Ethical Challenges in Randomized Controlled Trials of Delirium Interventions for Older Adults: A Rapid Review. PMID 41698182 · Anesth Analg · 2026-Feb-16 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Control arm overperformance in phase 3 oncology clinical trials. PMID 41653086 · Cancer · 2026-Feb-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Is Clinical Remission, an Ambitious Treatment Goal, Achievable in Patients with Moderate-to-Severe Asthma on Inhaled Therapies: How Ambitious Should We Be? PMID 41753185 · J Clin Med · 2026-Feb-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Proton versus photon radiotherapy in adults with primary brain tumors evaluating functional survival: a phase 3 randomized controlled trial study protocol (PRIDE). PMID 41689093 · Radiat Oncol · 2026-Feb-14 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A randomised trial of a bioreactor-produced EV-A71 vaccine for endemic control in children. PMID 41680199 · NPJ Vaccines · 2026-Feb-12 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Fibrin sealant for prophylaxis of cervical anastomotic leakage after McKeown esophagectomy for esophageal or esophagogastric junction cancer (PLACE030): a Phase III multicenter randomized clinical trial. PMID 41677267 · Int J Surg · 2026-Feb-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn's disease: subgroup analysis of the Phase 3 GRAVITI study. PMID 41674029 · Intest Res · 2026-Feb-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Comparing and combining xevinapant with ATR and PARP inhibition for the radiosensitization of HPV-negative HNSCC cells. PMID 41673235 · Sci Rep · 2026-Feb-11 The record describes a preclinical study in cell lines comparing different radiosensitizing approaches. While it mentions a Phase 3 trial (TrilynX), the study itself is not a report of that trial's results. It is a laboratory investigation, not a clinical trial result report, and does not present a time-to-event efficacy endpoint (OS, PFS, etc.) from a human trial.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study. PMID 41670439 · Arthritis Rheumatol · 2026-Feb-11 The study is a Phase 3 randomized, placebo-controlled trial of guselkumab (a drug intervention) in human patients with psoriatic arthritis. However, it is not an oncology study (psoriatic arthritis is a rheumatologic condition), and the reported efficacy endpoints are clinical response measures (ACR20, PASI90, etc.), not time-to-event outcomes (e.g., OS, PFS, DFS, EFS, RFS, TTP) analyzed via Kaplan-Meier or hazard ratios. Therefore, it does not meet the oncology or time-to-event criteria for inclusion.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Quadruple vs triple therapy for resistant hypertension: the QUADRO trial. PMID 41667119 · Eur Heart J · 2026-Feb-11 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Advances in Immunotherapy for Breast Cancer. PMID 41701864 · Oncology (Williston Park) · 2026-Feb-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Predictors of Efficacy Maintenance After Vunakizumab Discontinuation in Patients With Moderate-to-Severe Plaque Psoriasis: A Post Hoc Analysis of a Randomized Controlled Trial. PMID 41665599 · Int J Dermatol · 2026-Feb-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
ESO annual stroke evidence update 2025. PMID 41706824 · Eur Stroke J · 2026-Feb-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification. PMID 40991667 · Clin Infect Dis · 2026-Feb-09 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of an educational intervention model on pesticide practices among farmers: a randomized controlled trial protocol. PMID 41654733 · BMC Public Health · 2026-Feb-07 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study. PMID 41649965 · J Neuromuscul Dis · 2026-Feb-06 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Doravirine versus dolutegravir-based regimen in antiretroviral treatment-naive people living with HIV-1 (ANRS0392s ELDORADO): protocol for an international, open-label, randomised, non-inferiority, phase III trial. PMID 41644158 · BMJ Open · 2026-Feb-05 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A descriptive comparison of phase 3 results and head-to-head trials in inflammatory bowel diseases. PMID 41609414 · J Crohns Colitis · 2026-Feb-05 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Somapacitan in children with idiopathic short stature: a randomized controlled phase 3 study. PMID 41712606 · Eur J Endocrinol · 2026-Feb-04 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Vunakizumab in patients with active psoriatic arthritis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 study. PMID 41632483 · Rheumatology (Oxford) · 2026-Feb-04 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Risk of hypertension in people with HIV in the USA initiating modern antiretroviral regimens: pooled analysis of blood pressure data from five clinical trials. PMID 41684244 · J Antimicrob Chemother · 2026-Feb-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Phase III triple-blind randomised placebo-controlled trial to evaluate effectiveness of early treatment with pregabalin to reduce pain severity after whiplash road traffic injury: study protocol for the PRioRTI Trial {1}. PMID 41629976 · Trials · 2026-Feb-02 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Fecal incontinence after prostate cancer irradiation: a systematic literature review. PMID 41629638 · Prostate Cancer Prostatic Dis · 2026-Feb-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Shortened High-dose Palliative Radiotherapy for Lung Cancer (SHiP-Rt): protocol for a single-arm, multicentre, phase II study. PMID 41628919 · BMJ Open · 2026-Feb-02 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials. PMID 40929381 · Eur Heart J Cardiovasc Pharmacother · 2026-Feb-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Trajectories and predictors of depressive and anxiety symptom improvement with adjunctive cariprazine in antidepressant-treated adults with major depression: A Bayesian mega-analysis of two randomized trials. PMID 41224012 · J Affect Disord · 2026-Feb-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Cefepime-enmetazobactam for complicated urinary tract infections: Redefining ESBL therapy. PMID 41949135 · Indian J Med Res · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A Randomized, Multicenter Study Evaluating the Efficacy, Safety and Tolerability of Dapagliflozin + Gliclazide Fixed Dose Combination Over Dapagliflozin Monotherapy in Type 2 Diabetes Mellitus Patients Inadequately Controlled on Metformin Monotherapy. PMID 41859618 · Cureus · 2026-Feb 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and efficacy of direct oral anticoagulants in pediatric oncology patients: real-world data from two quaternary care pediatric centers. PMID 41853582 · Res Pract Thromb Haemost · 2026-Feb This is a retrospective cohort study (non-randomized) of direct oral anticoagulants in pediatric oncology patients. While it is oncology, human, and reports original results on a drug intervention, it lacks the required randomized controlled trial design (Phase III/IIIb or II/III) and does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR analysis. The primary endpoints are safety (bleeding) and efficacy (recurrent thrombosis), which are event rates, not time-to-event outcomes.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cardiovascular Outcomes Associated With Biologic Therapy in Inflammatory Dermatologic Diseases: A Systematic Review. PMID 41822639 · Cureus · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Bridging paradigms and shaping the future of resectable gastric cancer: a narrative review of the post-MATTERHORN era. PMID 41809424 · Gastroenterol Rep (Oxf) · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Aetiology of sepsis in adults living with HIV in East Africa: a secondary analysis of an open-label, multicentre, randomised, controlled phase 3 trial. PMID 41768988 · EClinicalMedicine · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
[CAR-T cell immunotherapy in early relapse after introduction chemoimmunotherapy]. PMID 41716107 · Recenti Prog Med · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Clinical Benefit of PD-1/PD-L1 Inhibitors as Standard First-Line Treatment in Low PD-L1-Expressing Advanced Solid Tumors: A Systematic Review and Meta-Analysis. PMID 41675360 · MedComm (2020) · 2026-Feb 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 3 Figure · 15 Panel · risk visible
Safety and immunogenicity of bivalent RSVpreF vaccine formulated in a multidose vial in healthy female participants in the USA: a multicentre, randomised, open-label, noninferiority phase 3 study. PMID 41660362 · EClinicalMedicine · 2026-Feb 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Introduction to the Supplement. PMID 41653006 · Muscle Nerve · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Survival of Intravenous Edaravone-Treated Patients With ALS: Evidence From Administrative Claims Analyses. PMID 41653004 · Muscle Nerve · 2026-Feb 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Optimizing vedolizumab therapy in ulcerative colitis: A critical synthesis of trial evidence and the emerging role of artificial intelligence. PMID 41642870 · PLOS Digit Health · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -